ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 31.734
AS - Asia 17.347
EU - Europa 9.395
SA - Sud America 2.445
Continente sconosciuto - Info sul continente non disponibili 539
AF - Africa 416
OC - Oceania 49
Totale 61.925
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.070
SG - Singapore 5.118
CN - Cina 3.418
HK - Hong Kong 3.029
VN - Vietnam 2.032
BR - Brasile 1.841
GB - Regno Unito 1.835
IT - Italia 1.834
BD - Bangladesh 1.176
FI - Finlandia 1.136
SE - Svezia 1.062
KR - Corea 720
RU - Federazione Russa 708
DE - Germania 626
FR - Francia 384
BG - Bulgaria 372
IN - India 361
PL - Polonia 360
CA - Canada 340
AR - Argentina 241
TR - Turchia 236
ID - Indonesia 228
NL - Olanda 176
UA - Ucraina 173
JP - Giappone 163
MX - Messico 158
ZA - Sudafrica 149
IQ - Iraq 145
AE - Emirati Arabi Uniti 126
ES - Italia 123
AT - Austria 108
CO - Colombia 84
LT - Lituania 77
PK - Pakistan 76
EC - Ecuador 74
IE - Irlanda 74
EG - Egitto 60
CL - Cile 57
MA - Marocco 54
SA - Arabia Saudita 54
CZ - Repubblica Ceca 51
UZ - Uzbekistan 51
PH - Filippine 46
VE - Venezuela 46
MY - Malesia 43
BE - Belgio 40
JO - Giordania 37
CR - Costa Rica 36
DZ - Algeria 36
PY - Paraguay 36
RO - Romania 36
AU - Australia 33
TN - Tunisia 31
KZ - Kazakistan 28
IL - Israele 27
NP - Nepal 26
PE - Perù 26
KE - Kenya 24
AZ - Azerbaigian 23
AL - Albania 22
TH - Thailandia 22
CH - Svizzera 21
ET - Etiopia 21
UY - Uruguay 20
HN - Honduras 19
IR - Iran 19
BO - Bolivia 18
GR - Grecia 18
JM - Giamaica 17
NO - Norvegia 17
PT - Portogallo 17
DO - Repubblica Dominicana 16
KG - Kirghizistan 15
A2 - ???statistics.table.value.countryCode.A2??? 14
BH - Bahrain 14
DK - Danimarca 14
TW - Taiwan 14
NZ - Nuova Zelanda 13
OM - Oman 13
RS - Serbia 13
LB - Libano 12
MK - Macedonia 12
GE - Georgia 11
MD - Moldavia 11
PR - Porto Rico 11
GT - Guatemala 10
HU - Ungheria 10
LV - Lettonia 10
QA - Qatar 10
EE - Estonia 9
KH - Cambogia 9
BY - Bielorussia 8
NI - Nicaragua 8
SK - Slovacchia (Repubblica Slovacca) 8
SV - El Salvador 8
TT - Trinidad e Tobago 8
CY - Cipro 7
HR - Croazia 7
BA - Bosnia-Erzegovina 6
LA - Repubblica Popolare Democratica del Laos 6
Totale 61.272
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.656
Ashburn 3.565
Singapore 3.275
Hong Kong 2.976
Fairfield 2.374
Chandler 2.080
Helsinki 1.087
New York 1.024
London 991
San Jose 961
Nyköping 857
Woodbridge 848
Houston 817
Wilmington 755
Hefei 706
Los Angeles 703
Seattle 703
Ho Chi Minh City 642
Cambridge 626
Beijing 610
Seoul 590
The Dalles 565
Hanoi 506
Chicago 504
Council Bluffs 499
Ann Arbor 477
San Diego 471
Princeton 372
Sofia 359
Southend 344
Warsaw 338
Milan 275
Buffalo 261
Piscataway 222
Moscow 221
Orem 217
North Bergen 215
Shanghai 195
Salt Lake City 194
Modena 185
Jersey City 180
São Paulo 174
Dallas 169
Secaucus 161
Jacksonville 160
Jakarta 155
Dearborn 152
Tokyo 120
Redondo Beach 115
Phoenix 111
Da Nang 110
Atlanta 106
Istanbul 105
Rome 104
Porto Alegre 97
Newark 96
Frankfurt am Main 93
Lauterbourg 90
Chennai 89
Clifton 89
Haiphong 87
Johannesburg 87
Bremen 86
Denver 85
Bupyeong-gu 84
Brooklyn 82
Toronto 80
San Francisco 77
Tampa 77
Bologna 70
Dublin 68
Montreal 68
Vienna 68
Elk Grove Village 66
Munich 66
Amsterdam 60
Mexico City 58
Norwalk 57
Rio de Janeiro 55
Stockholm 53
Charlotte 52
Manchester 52
Miano 52
Nuremberg 52
Naples 51
Viroflay 51
Augusta 50
Miami 49
Paris 49
Guangzhou 48
Izmir 48
Philadelphia 47
Boardman 46
Des Moines 46
Baghdad 45
Biên Hòa 45
Reading 45
Detroit 44
Kent 44
Kilburn 44
Totale 41.136
Salva come PNG Salva come JPEG
Nome #
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 1.142
Non-alcoholic steatohepatitis and liver transplantation 524
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis 466
Side Effects of Immunosuppressant Drugs After Liver Transplant 451
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 387
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 386
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 364
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 353
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 349
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 340
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 336
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 325
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 323
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 323
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 323
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 316
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 307
From current status to optimization of HCV treatment: Recommendations from an expert panel 297
Missed treatment in an Italian HBV infected patients cohort: HBV RER 295
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 288
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 281
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 278
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 275
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 271
Global multi-stakeholder endorsement of the MAFLD definition 266
Treatment of nonalcoholic steatohepatitis in adults: present and future 260
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 259
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 258
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 257
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 255
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 255
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 252
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 249
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 244
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 240
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 240
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 239
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 239
Adaptive response in Hepatitis B virus infection 239
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 237
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 236
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 236
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 233
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 231
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 229
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 228
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study 226
Characteristics of hepatocellular carcinoma in Italy 226
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 226
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 225
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 224
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 224
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 220
Alcohol and viral hepatitis: a mini-review 218
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 217
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 216
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 215
Update on Alcohol and Viral Hepatitis 212
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 212
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 212
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 209
CD 133+ stem cells for the treatment of end stage liver disease 208
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 207
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 206
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 204
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 204
Gross pathologic types of hepatocellular carcinoma in Italy. 203
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 203
Clinical and serological profile of primary biliary cirrhosis in men 202
Detection of HCV antigens in liver graft: Relevance to the management of recurrent post-liver transplant hepatitis C 202
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 201
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 201
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 201
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 200
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 199
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 199
Chronic hepatitis B: Are we close to a cure? 199
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 198
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 198
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): A randomised, double-blind, non-inferiority phase 3 trial 198
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 197
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 197
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 196
Familial intrahepatic cholestasis: New and wide perspectives 194
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 193
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 190
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 190
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 189
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 188
Virological Treatment Monitoring for Chronic Hepatitis B 187
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 186
Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis 186
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 185
Characterization of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver 184
Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy 183
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 183
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 182
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 182
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants 181
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 181
Totale 25.251
Salva come PNG Salva come JPEG
Categoria #
all - tutte 311.241
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 311.241
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.712 823 485 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202627.515 1.254 771 1.937 2.630 3.300 2.823 3.041 1.658 2.592 2.540 2.539 2.430
2026/20271.804 1.804 0 0 0 0 0 0 0 0 0 0 0
Totale 61.925